Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights (GlobeNewswire) - Feb 24, 2022 - "The Company's near- and mid-term business objectives include the following: Other Indications: (i) Complete initial cohort enrollment and feasibility assessment in ReSPECT-LM Phase 1 trial; (ii) Obtain FDA approval of Investigational New Drug (IND) application for Phase 1 trial of 186RNL in patients with pediatric brain cancer (ReSPECT-PBC)."
IND • Trial status • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|